Pathophysiology of antipsychotic drug-induced movement disorders

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 9, 2004, Pages 25-28

  Casey, Daniel E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR;

AGE; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DYSKINESIA, DRUG-INDUCED; HUMANS; MODELS, BIOLOGICAL; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEX FACTORS;

EID: 3042826534     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press; 2000
2. Spina E, Sturiale V, Valvo S, et al. Prevalence of aente dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol 1993;8:21-24
3. Gershanik OS. Drug-induced parkinsonism in the aged: recognition and prevention. Drugs Aging 1994;5: 127-132
4. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719
5. Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1497-1502
6. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell; 1995:546-565
7. Kane JM. Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatnc Association. Washington, D.C.: American Psychiatric Association; 1992
8. Yokoi F, Grunder O, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002;27:248-259
9. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin pKi values. J Pharmacol Exp Ther 1989;251:238-246
10. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002:47:27-38
11. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001;158:360-369
12. Stahl SM. "Hit-and-run" actions at dopamine receptors, Pt 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics [BRAINSTORMS]. J Clin Psychiatry 2001;62:747-748
13. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-166
14. Gogtay N, Sporn A, Alfaro CL, et al. Clozapine-induced akathisia in children with schizophrenia. J Child Adolesc Psychopharmacol 2002;12:347-349
15. Klawans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 1972;33:235-246
16. Tarsy D, Baldessarini RJ. Pharmacologically induced behavioral supersensitivity to apomorphine. Nature 1973;245:262-263
17. Waddington IL, Cross AJ, Gamble SJ, et al. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 1983;29:530-532
18. Crow TJ, Cross AJ, Johnstone EC, et al. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? are they associated with changes in dopamine receptors? J Clin Psychopharmacol 1982:2:336-340
19. Mihara K, Kondo T, Higuchi H, et al. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet 2002;8:693-695